Stocktoria
QUEST DIAGNOSTICS INC DGX
QUEST DIAGNOSTICS INC (DGX) earns a Piotroski F-score of 7/9 (strong financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 1.52% (safety: safe). FY2025 revenue was $11.0B at a 9.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.68 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-07-28 | JP Morgan | Neutral (main) |
| 2026-07-25 | UBS | Neutral (main) |
| 2026-07-24 | Mizuho | Outperform (main) |
| 2026-07-24 | Truist Securities | Hold (main) |
| 2026-07-24 | Barclays | Overweight (main) |
| 2026-07-24 | Baird | Neutral (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 7/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.006 |
| Retained earnings / assets | 0.616 |
| EBIT / assets | 0.096 |
| Equity / liabilities | 0.799 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| DGX | QUEST DIAGNOSTICS INC | 7/9 | 3.53 | 23.4 | +11.8% |
| LH | LABCORP HOLDINGS INC. | 8/9 | 3.39 | 25.4 | +7.2% |
| FTRE | Fortrea Holdings Inc. | 3/9 | -3.58 | — | +1% |
| NTRA | Natera, Inc. | 3/9 | 0.87 | — | +35.9% |
| RDNT | RadNet, Inc. | 3/9 | 1.4 | — | +11.5% |
| GH | Guardant Health, Inc. | 4/9 | -2.57 | — | +32.9% |
| VCYT | VERACYTE, INC. | 7/9 | 15.66 | 61.2 | +16% |
About QUEST DIAGNOSTICS INC
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
FAQ
Is DGX financially healthy?
QUEST DIAGNOSTICS INC's Piotroski F-score is 7/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does DGX pay a dividend, and is it safe?
Yes. QUEST DIAGNOSTICS INC pays a dividend yielding about 1.52% with a 35.6% payout ratio, rated “safe” for safety.
How profitable is DGX?
In FY2025, QUEST DIAGNOSTICS INC had a net margin of 9.0% and a return on equity of 13.8%.
Is DGX overvalued or undervalued?
QUEST DIAGNOSTICS INC trades at about 27.2× trailing earnings — above its 10-year norm (10-year range 8.7×–21.4×, median 18.6×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for DGX?
The average Wall-Street price target for QUEST DIAGNOSTICS INC is $245.87, about 3.4% above the recent price, from 15 analysts (consensus: buy).
Is DGX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on QUEST DIAGNOSTICS INC: a Piotroski F-score of 7/9, an Altman Z″ in the safe zone, a P/E of about 23.4×, a dividend yield of 1.52%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.